Nuvation Bio Inc.
Nuvation Bio is a global oncology company that develops and commercializes cancer therapies for patients. It focuses on oncology targets supported by clinical or preclinical data and uses medicinal chemistry to develop small-molecule drug candidates and drug-drug conjugates. Its commercial product IBTROZI, or taletrectinib, is an oral ROS1 inhibitor approved in the U.S. for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer. Nuvation Bio also evaluates taletrectinib in clinical studies and commercializes it through partners in Japan and China, with Eisai licensed to develop and commercialize it in specified territories. Its clinical-stage pipeline includes safusidenib, an inhibitor of mutant IDH1 being studied for IDH1-mutant astrocytoma, and candidates from its drug-drug conjugate platform. Nuvation Bio earns money through sales of IBTROZI and may receive upfront, milestone and royalty payments under licensing and collaboration agreements. It is headquartered in New York, New York.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $NUVB in the last 30 days.
See all $NUVB insider activity →Nuvation Bio (NUVB) reported Q3 GAAP EPS of -$0.12, matching estimates. Revenue was $45M, up 243% year-over-year and exceeding expectations by $10.58M. The company has been active in recent healthcare conferences.
Nuvation Bio (NYSE: NUVB) reported Q3 2026 revenue of $45.0M, with $27.5M from IBTROZI®. IBTROZI, a ROS1 TKI, is the market leader in new patient starts and total active patients. FDA approved a label update for IBTROZI, reflecting a 49.7-month median duration of response. The FDA granted Fast Track Designation to safusidenib for IDH1-mutant glioma. The company had $663.4M in cash as of September 30, 2026.
Nuvation Bio (NYSE: NUVB) will present updated Phase 2 results and ongoing trial overviews for safusidenib, its investigational IDH1 inhibitor, at the 2026 SNO Annual Meeting. The presentation includes additional data from the Phase 2 J201 study, previously announced in July 2026. Safusidenib is being studied for IDH1-mutant glioma, a type of brain cancer with significant unmet medical needs.
Over the past 7 days, AlphAI's AI scored 6 news stories mentioning NUVB (Nuvation Bio Inc.). Coverage has skewed bullish: 3 bullish, 2 neutral, and 1 bearish.
Recent NUVB coverage spans regulation, earnings and financial news.
Earnings beat on revenue but EPS miss may cause mixed short-term reaction.
Positive earnings beat and FDA approval likely support share price appreciation.
The fresh clinical data could drive short‑term volatility; positive results may lift the stock, while any setbacks could pressure it.
The trial expansion signals progress and may improve investor sentiment.
The announcement provides a date for the upcoming earnings release but contains no new financial data.
AlphAI scores every news story that mentions NUVB with an AI model for sentiment and relevance, and aggregates insider trades from Nuvation Bio Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Nuvation Bio (NUVB) reported Q3 GAAP EPS of -$0.12, matching estimates. Revenue was $45M, up 243% year-over-year and exceeding expectations by $10.58M. The company has been active in recent healthcare conferences.
Nuvation Bio (NYSE: NUVB) reported Q3 2026 revenue of $45.0M, with $27.5M from IBTROZI®. IBTROZI, a ROS1 TKI, is the market leader in new patient starts and total active patients. FDA approved a label update for IBTROZI, reflecting a 49.7-month median duration of response. The FDA granted Fast Track Designation to safusidenib for IDH1-mutant glioma. The company had $663.4M in cash as of September 30, 2026.
Nuvation Bio (NYSE: NUVB) will present updated Phase 2 results and ongoing trial overviews for safusidenib, its investigational IDH1 inhibitor, at the 2026 SNO Annual Meeting. The presentation includes additional data from the Phase 2 J201 study, previously announced in July 2026. Safusidenib is being studied for IDH1-mutant glioma, a type of brain cancer with significant unmet medical needs.
Nuvation Bio (NUVB) is expanding its Phase 3 SIGMA trial of safusidenib to six European countries, adding to existing sites in the U.S., Australia, China, Canada, and Japan. The expansion follows the drug's Fast Track designation. According to the company, the trial aims to meet enrollment goals and deliver positive progression-free survival results.
Nuvation Bio (NYSE: NUVB) will report Q3 2026 financial results and provide a business update on November 4, 2026. The company, focused on oncology, will host a conference call and webcast. Investors can register via the company's website. Nuvation Bio's pipeline includes taletrectinib, safusidenib, and a drug-drug conjugate program.
Citizens reiterated a Market Outperform rating and $10.00 price target on Nuvation Bio (NYSE:NUVB), citing solid Q3 performance and expectations of a full-year beat. The firm forecasts $29.2M in Q3 2026 Ibtrozi revenue, up 28% QoQ. NUVB stock has fallen 50% YTD despite a 25% drop in the last three months. Analysts highlight the drug's strong clinical data and market potential.
Citigroup initiated coverage on Nuvation Bio (NUVB) and Jazz Pharmaceuticals (JAZZ) with Buy ratings. NUVB received a $12 price target, citing strong sales of Ibtrozi and potential of safusidenib. JAZZ was given a $320 target, highlighting Ziihera's growth potential. Both stocks are seen as covered call opportunities.
Ultragenyx (RARE) gained FDA approval for FAYUVI, a treatment for Sanfilippo syndrome Type A, closing at $14.50, up 12.58%. Nuvation Bio (NUVB) expanded IBTROZI's label with new lung cancer data, closing at $6.07, up 5.02%. Bayer (BAYRY) won FDA approval for Kerendia in type 1 diabetes-related CKD, closing at $14.13, up 0.57%. Biogen (BIIB) and Eisai (ESALY.PK) received Japan approval for LEQEMBI Pen, closing at $219.05, up 1.41%. Telix (TLX) got FDA approval for Pixclara, a PET imaging agent fo
Nuvation Bio (NUVB) shares rose premarket after the FDA approved a label update for its cancer therapy Ibtrozi, including new mid-stage trial data. The update followed a supplemental New Drug Application approval.
Nuvation Bio (NUVB) announced FDA approval of its supplemental New Drug Application for IBTROZI (taletrectinib), updating the label to reflect a median duration of response of 49.7 months in TKI-naïve advanced ROS1-positive NSCLC patients. The approval, four months ahead of schedule, includes no new safety signals. IBTROZI is already approved in the U.S., Japan, and China, with regulatory reviews ongoing in Europe and the UK.
